Apexicon E
Pricing Report NDC 10337-395-30
Current Package Pricing Information
The latest wholesale acquisition cost for Apexicon E (NDC 10337-395-30) is $18.86506 per GM. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Dec 31, 2017.
As a provided by Pharmaderm A Division Of Fougera Pharmaceuticals Inc., this medication is distributed in a 1 TUBE in 1 CARTON / 30 g in 1 TUBE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.
NADAC Pricing Summary
NADAC pricing snapshot for this package NDC
Acquisition Cost $18.86506 Per GM
The NADAC was calculated based on package size.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Historical Pricing Trends & Acquisition Cost Benchmarks
Since Sep 2013, the NADAC wholesale price for (NDC ) has moved within a range of $7.25508 to $18.86506 per GM. Over this 4 years and 3 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.
$7.2551 - $18.8651
160.03% Variance
8.00%
| Date | Unit Price | Unit | Source | Method | Rate |
|---|---|---|---|---|---|
| Dec 31, 2017 | $18.86506 | GM | C/I - Chain or Independent Pharmacy | Code 3, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Dec 31, 2017 | $18.86506 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Dec 31, 2016 | $17.46765 | GM | C/I - Chain or Independent Pharmacy | Code 3, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Dec 31, 2016 | $17.46765 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 26, 2016 | $16.02536 | GM | C/I - Chain or Independent Pharmacy | Code 3, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 26, 2016 | $16.02536 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 18, 2015 | $14.70203 | GM | C/I - Chain or Independent Pharmacy | Code 2, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 18, 2015 | $14.70203 | GM | C/I - Chain or Independent Pharmacy | Code 3, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 18, 2015 | $14.70203 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | B-ANDA - Abbreviated New Drug Application |
| Mar 19, 2014 | $13.27063 | GM | C/I - Chain or Independent Pharmacy | Code 1, 5 | G - Generic |
| Mar 19, 2014 | $13.27063 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5 | G - Generic |
| Dec 18, 2013 | $7.25508 | GM | C/I - Chain or Independent Pharmacy | Code 1, 5 | G - Generic |
| Dec 18, 2013 | $7.25508 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5 | G - Generic |
| Sep 19, 2013 | $7.32203 | GM | C/I - Chain or Independent Pharmacy | Code 4, 5 | G - Generic |
Pricing Methodology Legend
- Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
- Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file.
- Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
- Code 4: The NADAC was carried forward from the previous file.
- Code 5: The NADAC was calculated based on package size.
- Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Understanding NADAC Pricing Data
The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.
Important Price Distinction:
The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.
NADAC Pricing Data Last Updated on: July 08, 2026
